Grant: Alliance Grants
University of Alberta
$49,000.00
Advanced surfaces for next generation hemodialysis technology._x000d_ _x000d_ _x000d_
EF 2020-21
Résumé
Although it is effective for sustaining life, modern hemodialysis has several important limitations. First, it is extremely expensive - average costs per patient exceed $120,000 per year, and may be substantially higher if complications occur. Second, it is associated with very high mortality - life expectancy for a 20-year-old hemodialysis patient is similar to life expectancy for a 75-year-old person with normal kidney function. Third, hemodialysis treatment leads to exceedingly poor quality of life - the average hemodialysis patient would trade ten years of life on hemodialysis for six years of life in normal health. Fourth, there are no means of diagnosing effectiveness of dialysis in the clinic - only two uremic toxins are evaluated using mass spectroscopy approaches. Fifth, although uremic toxins are recognized as contributors to progressive kidney dysfunction there are no known approaches for targeting these molecules to remove them from patient blood. Sixth, membrane approaches will never clear some of these toxins as they become closely associated with proteins. We need to advance dialysis technology to overcome significant costs to patients, the healthcare system, and environmental damage associated to hemodialysis.
To overcome this problem state-of-the-art techniques for engineering new polymer-modified surfaces will be used to bind and remove uremic toxins from blood - competing with proteins as artificial binders of these toxins. This will be accomplished by forming artificial binding pockets using both polymer and biopolymer architectures for the sole purpose of developing reusable surfaces that bind uremic toxins. Unsworth labs has extensive experience in building polymers on surfaces as required for this approach. We will move this advanced technology to new products in the area of off-line diagnostics, in-line diagnostics, and increased therapeutic potential by augmenting existing membrane dialysis technology.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
561123-2020
Name nom
Unsworth, Larry
Department département
Chemical and Materials Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
49000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Advanced surfaces for next generation hemodialysis technology._x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
Although it is effective for sustaining life, modern hemodialysis has several important limitations. First, it is extremely expensive - average costs per patient exceed $120,000 per year, and may be substantially higher if complications occur. Second, it is associated with very high mortality - life expectancy for a 20-year-old hemodialysis patient is similar to life expectancy for a 75-year-old person with normal kidney function. Third, hemodialysis treatment leads to exceedingly poor quality of life - the average hemodialysis patient would trade ten years of life on hemodialysis for six years of life in normal health. Fourth, there are no means of diagnosing effectiveness of dialysis in the clinic - only two uremic toxins are evaluated using mass spectroscopy approaches. Fifth, although uremic toxins are recognized as contributors to progressive kidney dysfunction there are no known approaches for targeting these molecules to remove them from patient blood. Sixth, membrane approaches will never clear some of these toxins as they become closely associated with proteins. We need to advance dialysis technology to overcome significant costs to patients, the healthcare system, and environmental damage associated to hemodialysis.
To overcome this problem state-of-the-art techniques for engineering new polymer-modified surfaces will be used to bind and remove uremic toxins from blood - competing with proteins as artificial binders of these toxins. This will be accomplished by forming artificial binding pockets using both polymer and biopolymer architectures for the sole purpose of developing reusable surfaces that bind uremic toxins. Unsworth labs has extensive experience in building polymers on surfaces as required for this approach. We will move this advanced technology to new products in the area of off-line diagnostics, in-line diagnostics, and increased therapeutic potential by augmenting existing membrane dialysis technology.